Related Experiment Video

Updated: Mar 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Association between the Matrix Metalloproteinase-9 rs3918242 Polymorphism and Ischemic Stroke Susceptibility: A

Tao He1, Jie Wang2, Xiao-Li Wang3

  • 1Department of Neurosurgery, Affiliated Hospital of Qingdao University, Qingdao, China.

Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association
|March 5, 2017
PubMed
Abstract

Insights

Matrix metalloproteinase (MMP)-9 rs3918242 variants are linked to a higher risk of ischemic stroke (IS). This association is particularly significant in the Chinese population, warranting further investigation into genetic predispositions for IS.

Area of Science:

  • Genetics
  • Neurology
  • Cardiovascular Disease

Background:

  • Numerous case-control studies suggest a link between matrix metalloproteinase (MMP)-9 rs3918242 variants and ischemic stroke (IS) susceptibility.
  • Previous findings have been equivocal, necessitating a comprehensive analysis to clarify the association.

Purpose of the Study:

  • To conduct a meta-analysis investigating the association between MMP-9 rs3918242 variants and the risk of IS.
  • To evaluate the risk under allelic and dominant genetic models.

Main Methods:

  • Searched five major databases for eligible studies up to October 2016.
  • Performed a meta-analysis using pooled odds ratios (ORs) and 95% confidence intervals (CIs).
  • Analyzed data under allelic (T vs. C) and dominant (TT+CT vs. CC) models.

Main Results:

  • Included 14 studies with 3233 IS cases and 3123 controls.
  • MMP-9 rs3918242 variants showed a significantly increased risk of IS in overall populations (OR=1.43, P<.001).
  • Subgroup analysis revealed increased IS risk in the Chinese population but not in Caucasians.

Conclusions:

  • MMP-9 rs3918242 variants (T allele, TT, and CT genotypes) significantly increase IS risk.
  • The association is specific to the Chinese population.
  • These findings highlight the role of MMP-9 rs3918242 in IS susceptibility among Chinese individuals.
Keywords:
MMP-9ischemic strokemeta-analysispolymorphism

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.9K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
16.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
74